VHL and renal cell carcinoma: These achievements largely stem from the elucidation of two inter-connected molecular pathways that regulate angiogenesis and proliferation in RCC, an inactivated von Hippel Lindau (VHL) gene and activated mammalian target of rapamycin (mTOR) (6–11).